Presented by: Edward Painter, A2A Pharmaceuticals

About Episode 7

In episode 7, Ed Painter brings his unique business perspective to drug discovery, attributing to the success of his organization, A2A Pharmaceuticals. A2A uses AI to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.

About Edward Painter

Former analyst at Goldman Sachs and Salomon Brothers, and former Senior VP at UBS, Oppenheimer & Co., Credit Suisse and Kidder Peabody, Edward Painter has more than 30 years of experience in finance. He has extensive experience working with biotech companies in financing and investment decisions.

Complete the form to the right for access to episode 7 of the Charles River Innovator's Series.


Also Available from the Charles River Innovator’s Series...


Ready to collaborate?

Connect with an Advisor